Literature DB >> 7785969

Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects.

A Shah1, J Lettieri, D Nix, J Wilton, A H Heller.   

Abstract

The effects of age and gender on the pharmacokinetics of high-dose intravenous ciprofloxacin in a healthy volunteer study were investigated. Plasma ciprofloxacin concentrations were higher in the elderly than in the young, and the pharmacokinetic parameters were not significantly different between the genders. Ciprofloxacin was well tolerated, with the majority of adverse events related to local reactions at the IV site.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7785969      PMCID： PMC162672          DOI： 10.1128/AAC.39.4.1003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

2.  Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients.

Authors:  A P Ball; C Fox; M E Ball; I R Brown; J V Willis
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

3.  Pharmacokinetics of ciprofloxacin in elderly subjects.

Authors:  M LeBel; G Barbeau; M G Bergeron; D Roy; F Vallée
Journal:  Pharmacotherapy       Date:  1986 Mar-Apr       Impact factor: 4.705

4.  Absolute oral bioavailability of ciprofloxacin.

Authors:  G L Drusano; H C Standiford; K Plaisance; A Forrest; J Leslie; J Caldwell
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Noncompartmental determination of the steady-state volume of distribution during multiple dosing.

Authors:  I L Smith; J J Schentag
Journal:  J Pharm Sci       Date:  1984-02       Impact factor: 3.534

6.  Dose- and sex-independent disposition of ciprofloxacin.

Authors:  D Höffler; A Dalhoff; W Gau; D Beermann; A Michl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191
  7 in total
  11 in total

1.  Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.

Authors:  S C Chien; A T Chow; J Natarajan; R R Williams; F A Wong; M C Rogge; R K Nayak
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.

Authors:  O Kozawa; T Uematsu; H Matsuno; M Niwa; S Nagashima; M Kanamaru
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

3.  Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.

Authors:  Paschalina Kontou; Kalliopi Chatzika; Georgia Pitsiou; Ioannis Stanopoulos; Paraskevi Argyropoulou-Pataka; Ioannis Kioumis
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

4.  Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.

Authors:  J Lipman; J Scribante; A G Gous; H Hon; S Tshukutsoane
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  The effect of ciprofloxacin on doxorubicin cytotoxic activity in the acquired resistance to doxorubicin in DU145 prostate carcinoma cells.

Authors:  Asieh Davary Avareshk; Jamileh Gholami; Razieh Jalal
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

7.  Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.

Authors:  J S Bertino; A N Nafziger
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 8.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 9.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

10.  Application of a Physiologically Based Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With Ciprofloxacin and Caffeine.

Authors:  A Navid; D M Ng; S E Wong; F C Lightstone
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.